{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:56Z","timestamp":1791414656501,"version":"4.3.3"},"reference-count":125,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.ejca.2003.12.004","type":"journal-article","created":{"date-parts":[[2004,1,27]],"date-time":"2004-01-27T05:22:43Z","timestamp":1075180963000},"page":"939-950","source":"Crossref","is-referenced-by-count":432,"title":["Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil"],"prefix":"10.1016","volume":"40","author":[{"given":"Andr\u00e9 B.P","family":"van Kuilenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2003.12.004_BIB1","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I","article-title":"The annual report to the nation on the status of cancer, 1973\u20131997, with a special section on colorectal cancer","volume":"88","author":"Ries","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB2","doi-asserted-by":"crossref","unstructured":"Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995, 345, 939\u2013944.","DOI":"10.1016\/S0140-6736(95)90696-7"},{"key":"10.1016\/j.ejca.2003.12.004_BIB3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/bmj.321.7260.531","article-title":"Palliative chemotherapy for advanced colorectal cancer","volume":"321","author":"Simmonds","year":"2000","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejca.2003.12.004_BIB4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1054\/bjoc.1999.1254","article-title":"Survival benefit of chemotherapy in metastatic colorectal cancer","volume":"82","author":"Jonker","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00000421-200204000-00005","article-title":"Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly","volume":"25","author":"Magn\u00e9","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer","volume":"16","author":"Meta-analysis Group In Cancer","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(02)00648-4","article-title":"Prediction of the response of colorectal cancer to systemic therapy","volume":"3","author":"Adlard","year":"2002","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/annonc\/mdf034","article-title":"Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer","volume":"13","author":"K\u00f6hne","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1011178111295","article-title":"Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer","volume":"12","author":"Volk","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2003.12.004_BIB11","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer","volume":"16","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14622416.3.4.485","article-title":"Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics","volume":"3","author":"Mattison","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejca.2003.12.004_BIB13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03256180","article-title":"The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil","volume":"21","author":"Gardiner","year":"2002","journal-title":"Adverse Drug React. Toxicol. Rev."},{"key":"10.1016\/j.ejca.2003.12.004_BIB14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/000456303321016150","article-title":"Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency","volume":"40","author":"van Kuilenburg","year":"2003","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ejca.2003.12.004_BIB15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0163-7258(90)90056-8","article-title":"Metabolism and mechanism of action of 5-fluorouracil","volume":"48","author":"Parker","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejca.2003.12.004_BIB16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1006416410198","article-title":"5-Fluorouracil","volume":"18","author":"Grem","year":"2000","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejca.2003.12.004_BIB17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0006-291X(85)91884-4","article-title":"The effect of 5-fluorouracil on DNA chain elongation in intact bone marrow cells","volume":"133","author":"Schuetz","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejca.2003.12.004_BIB18","first-page":"119","article-title":"Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil","volume":"46","author":"Schuetz","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB19","first-page":"322","article-title":"Cell surface alterations associated with exposure of leukemia L1210 cells to fluorouracil","volume":"40","author":"Kessel","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/0277-5379(90)90029-S","article-title":"Do antimetabolites interfere with the glycosylation of cellular glycoconjugates?","volume":"26","author":"Peters","year":"1990","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB21","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.1997.15.10.3223","article-title":"Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin","volume":"15","author":"Leichman","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.1999.17.6.1760","article-title":"Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy","volume":"17","author":"Aschele","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB23","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1054\/bjoc.2001.2007","article-title":"A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil","volume":"85","author":"Iacopetta","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.1997.15.1.368","article-title":"Fluorouracil in colorectal cancer\u2014a tale of two drugs","volume":"15","author":"Sobrero","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients","volume":"45","author":"Sch\u00fcller","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB27","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB28","first-page":"5405","article-title":"Enzymes of uracil catabolism in normal and neoplastic human tissues","volume":"45","author":"Naguib","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6690097","article-title":"Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells","volume":"79","author":"van Kuilenburg","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0959-8049(97)00345-6","article-title":"Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis","volume":"34","author":"Etienne","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0002-9343(99)80259-9","article-title":"Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities","volume":"99","author":"St\u00e9phan","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejca.2003.12.004_BIB32","first-page":"507","article-title":"Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver","volume":"2","author":"Chazal","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB33","first-page":"197","article-title":"Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion","volume":"50","author":"Harris","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0959-8049(02)00598-1","article-title":"Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver","volume":"39","author":"Porsin","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800050635","article-title":"Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells","volume":"40","author":"Grem","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/978-1-4615-5381-6_156","article-title":"No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil","volume":"431","author":"van Kuilenburg","year":"1998","journal-title":"Advances in Experimental Medicine & Biology"},{"key":"10.1016\/j.ejca.2003.12.004_BIB37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00432-001-0309-y","article-title":"Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls","volume":"128","author":"Raida","year":"2002","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB38","first-page":"1347","article-title":"High inter- and intrapatient variantion in 5-Florouracil plama concentrations during a prolonged drug infusion","volume":"5","author":"Takimoto","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB39","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB40","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1023\/A:1012294617392","article-title":"Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients","volume":"12","author":"Di Paolo","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00280-003-0568-1","article-title":"Intermittent FLDP","volume":"51","author":"Terashima","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB42","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6600208","article-title":"Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene","volume":"86","author":"Maring","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejca.2003.12.004_BIB44","first-page":"270","article-title":"Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs","volume":"25","author":"Okuda","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejca.2003.12.004_BIB45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2125.1998.00050.x","article-title":"Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase","volume":"46","author":"Diasio","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/bjc.1998.73","article-title":"Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours","volume":"77","author":"McLeod","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB47","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.1996.14.5.1663","article-title":"Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer","volume":"14","author":"Vokes","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB48","first-page":"3789","article-title":"Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer","volume":"22","author":"Saeki","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB49","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/0959-8049(94)00216-R","article-title":"A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil","volume":"30A","author":"Beck","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/73439","article-title":"A gene expression database for the molecular pharmacology of cancer","volume":"24","author":"Scherf","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejca.2003.12.004_BIB51","first-page":"883","article-title":"Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice","volume":"5","author":"Ishikawa","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB52","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.cgt.7700393","article-title":"Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells","volume":"8","author":"Takebe","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejca.2003.12.004_BIB53","first-page":"2566","article-title":"Regulation of dihydropyrimidine dehydrogenase in colorectal cancer","volume":"5","author":"Johnston","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB54","first-page":"999","article-title":"Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen","volume":"7","author":"Grem","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB55","first-page":"705","article-title":"Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa","volume":"18","author":"Miyamoto","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB56","first-page":"2836","article-title":"Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer","volume":"5","author":"Uetake","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB57","first-page":"4116","article-title":"Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels","volume":"9","author":"Kornmann","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00423-002-0313-y","article-title":"Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis","volume":"387","author":"Ikeguchi","year":"2002","journal-title":"Langenbecks Arch. Surg."},{"key":"10.1016\/j.ejca.2003.12.004_BIB59","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.1995.13.7.1663","article-title":"Response to fluorouracil therapy in cancer patients","volume":"13","author":"Etienne","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB60","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/sj.bjc.6690297","article-title":"A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil","volume":"79","author":"Etienne","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB61","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1349-7006.1998.tb00509.x","article-title":"Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice","volume":"89","author":"Takechi","year":"1998","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB62","first-page":"2783","article-title":"Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels","volume":"7","author":"Tanaka-Nozaki","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB63","first-page":"359","article-title":"Regulation of dihydropyrimidine dehydrogenase gene expression in regenerating mouse liver","volume":"22","author":"Tamada","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB64","first-page":"1004","article-title":"Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas","volume":"31","author":"Queener","year":"1971","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB65","first-page":"395","article-title":"Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma","volume":"3","author":"Jiang","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB66","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0304-3835(02)00435-4","article-title":"Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers","volume":"188","author":"Yamashita","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejca.2003.12.004_BIB67","first-page":"786","article-title":"Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer","volume":"9","author":"Ichikawa","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB68","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.bjc.6601335","article-title":"Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer","volume":"89","author":"Ichikawa","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1040-8428(98)00036-5","article-title":"Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer \u2014 status of the art","volume":"30","author":"Gamelin","year":"1999","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB70","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000011897","article-title":"Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients","volume":"55","author":"Katona","year":"1998","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2003.12.004_BIB71","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1172\/JCI118830","article-title":"Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity","volume":"98","author":"Wei","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejca.2003.12.004_BIB72","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0959-8049(97)00261-X","article-title":"Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity","volume":"33","author":"van Kuilenburg","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB73","first-page":"2999","article-title":"Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity","volume":"4","author":"Kouwaki","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB74","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","article-title":"Known variant DPYD alleles do not explain DPD deficiency in cancer patients","volume":"10","author":"Collie-Duguid","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejca.2003.12.004_BIB75","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB76","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB77","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil","volume":"7","author":"van Kuilenburg","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB78","first-page":"2832","article-title":"Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls","volume":"7","author":"Raida","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB79","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency","volume":"101","author":"van Kuilenburg","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB81","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/annonc\/mdg056","article-title":"Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene","volume":"14","author":"van Kuilenburg","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB82","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200210000-00007","article-title":"High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity","volume":"12","author":"van Kuilenburg","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejca.2003.12.004_BIB83","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity","volume":"79","author":"Milano","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB84","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.ejca.2003.12.004_BIB85","first-page":"5433","article-title":"Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver","volume":"53","author":"Lu","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB86","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB87","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.20.6.1491","article-title":"Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer","volume":"20","author":"Sloan","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB88","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/emboj\/20.4.650","article-title":"Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil","volume":"20","author":"Dobritzsch","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.ejca.2003.12.004_BIB89","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/bj3640157","article-title":"Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure","volume":"364","author":"van Kuilenburg","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejca.2003.12.004_BIB90","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1006\/geno.1994.1680","article-title":"Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridisation","volume":"24","author":"Takai","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.ejca.2003.12.004_BIB91","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/geno.1998.5379","article-title":"Characterization of the human dihydropyrimidine dehydrogenase gene","volume":"51","author":"Wei","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.ejca.2003.12.004_BIB92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"van Kuilenburg","year":"1999","journal-title":"Human Genetics"},{"key":"10.1016\/j.ejca.2003.12.004_BIB93","first-page":"1096","article-title":"Identification of a novel disease-causing mutation (100delA) in the dihydropyrimidine dehydrogenase gene","volume":"1","author":"van Kuilenburg","year":"2002","journal-title":"Int. Arch. Biocsi."},{"key":"10.1016\/j.ejca.2003.12.004_BIB94","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1349-7006.2001.tb01100.x","article-title":"Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil","volume":"92","author":"Yamaguchi","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB95","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/BF01799841","article-title":"A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency","volume":"19","author":"Vreken","year":"1996","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejca.2003.12.004_BIB96","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2125.1998.00751.x","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects","volume":"46","author":"Ridge","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB97","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/clinchem\/46.2.309","article-title":"Common DPYD mutation associated with 5-fluorouracil toxicity detected by PCR-mediated site-directed mutagenisis","volume":"46","author":"Stott","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejca.2003.12.004_BIB98","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0009-9120(01)00188-6","article-title":"Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes","volume":"34","author":"Nauck","year":"2001","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejca.2003.12.004_BIB99","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1373\/49.10.1661","article-title":"Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase","volume":"49","author":"Ahluwalia","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejca.2003.12.004_BIB100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abio.2002.5666","article-title":"A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency","volume":"306","author":"Ezzeldin","year":"2002","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejca.2003.12.004_BIB101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/109065703322146777","article-title":"Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography","volume":"7","author":"Fischer","year":"2003","journal-title":"Genet. Test"},{"key":"10.1016\/j.ejca.2003.12.004_BIB102","first-page":"325","article-title":"High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism","volume":"22","author":"Gross","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","article-title":"Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency","volume":"46","author":"van Kuilenburg","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejca.2003.12.004_BIB104","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer","volume":"17","author":"Gamelin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB105","first-page":"1315","article-title":"Reply","volume":"8","author":"Behnke","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB106","series-title":"Calculations. Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"key":"10.1016\/j.ejca.2003.12.004_BIB107","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1634\/theoncologist.7-4-288","article-title":"Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1)","volume":"7","author":"Malet-Martino","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2003.12.004_BIB108","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008337900349","article-title":"MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)","volume":"11","author":"Toffoli","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.tpj.6500012","article-title":"Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy","volume":"1","author":"Pullarkat","year":"2001","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.ejca.2003.12.004_BIB110","first-page":"4363","article-title":"Dihydropyrimidinase deficiency and severe 5-Fluorouracil toxicity","volume":"9","author":"van Kuilenburg","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB111","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1091-255X(02)00018-5","article-title":"Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer","volume":"6","author":"Kornmann","year":"2002","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.ejca.2003.12.004_BIB112","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1200\/JCO.2002.09.091","article-title":"Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy","volume":"20","author":"Etienne","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB113","first-page":"761","article-title":"Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer","volume":"22","author":"Terashima","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB114","first-page":"889","article-title":"Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy","volume":"17","author":"Takabayashi","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB115","first-page":"5635","article-title":"Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer","volume":"19","author":"Ishikawa","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejca.2003.12.004_BIB116","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-002-0422-x","article-title":"Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma","volume":"49","author":"Nozawa","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB117","first-page":"653","article-title":"Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer","volume":"17","author":"Miyamoto","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB118","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/S0959-8049(02)00380-5","article-title":"Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients","volume":"38","author":"Terashima","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB119","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jso.10137","article-title":"Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur+Uracil) in patients with p-stage I nonsmall-cell lung cancer","volume":"81","author":"Nakagawa","year":"2002","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB120","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1200\/JCO.2000.18.23.3946","article-title":"Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer","volume":"18","author":"Fujiwaki","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB121","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.bjc.6600040","article-title":"Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer","volume":"86","author":"Horiguchi","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB122","first-page":"953","article-title":"Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer","volume":"19","author":"Hoque","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejca.2003.12.004_BIB123","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1067\/moe.2002.126912","article-title":"Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma","volume":"94","author":"Kawasaki","year":"2002","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"10.1016\/j.ejca.2003.12.004_BIB124","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0959-8049(00)00440-8","article-title":"The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer","volume":"37","author":"Mizutani","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.12.004_BIB125","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1081\/CNV-120001178","article-title":"Dihydropyrimidine dehydrogenase enzyme deficiency","volume":"20","author":"\u00c7elik","year":"2002","journal-title":"Cancer Invest."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804903010694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804903010694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T06:39:18Z","timestamp":1585463958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804903010694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":125,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0959804903010694"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2003.12.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}